Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Gynecologic Cancers
•
Endometrial Cancer
For a diabetic patient with presumed stage I Grade 1 endometrial cancer, what Hemoglobin A1C level would prompt you to recommend medical management instead of surgery?
Related Questions
For a patient with IIIC endometrial adenocarcinoma diagnosed and treated with 6 cycles of Carboplatin/Paclitaxel two years prior, would you consider maintenance therapy with PD-L1 inhibition, given results of GY018 and RUBY?
Would you consider the addition of trastuzumab to carboplatin/paclitaxel for an advanced uterine carcinosarcoma that stains HER2 IHC 3+ in the carcinomatous components but IHC 0 in the sarcomatous regions?
Would you incorporate a PARP inhibitor into the management of a patient with endometrial cancer with a germline or somatic BRCA mutation?
When treating endometrial cancer patients with a combination of chemotherapy and vaginal cuff brachytherapy, when do you deliver cuff brachy?
Does the path length of vaginal cuff cylinder brachytherapy treatment as adjuvant therapy for endometrial cancer vary based on histology (serous, etc)?
Do you recommend a completion hysterectomy to patients who undergo primary radiation for endometrial cancer (presuming they are now a surgical candidate)?
For a medically inoperable clinically-staged FIGO IA endometrial cancer with serous, clear cell or other non-endometrioid, high-risk histology treated with EBRT alone, would you cover elective lymph nodes, or treat the uterus alone?
What adjuvant therapy would you recommend for IA G3 endometrioid endometrial adenocarcinoma with no LVSI, MMR intact, p53wt and POLEmut?
Would you consider offering immunotherapy +/- olaparib to a patient with early-stage endometrial carcinoma for whom you are recommending adjuvant chemotherapy based on improved outcomes seen in RUBY/DUO-E/NRG-GY018?
How do you classify extensive LVSI in endometrial cancer?